Yarrow Bioscience, Inc. (YARW) is a Nasdaq-listed, clinical-stage biotechnology company developing therapies for autoimmune thyroid disease. Its lead asset, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR), designed as a potentially first-in-class subcutaneous treatment for Graves' disease and thyroid eye disease. The company was formed in July 2026 when VYNE Therapeutics merged with Yarrow Bioscience, and it employs a staff of just seven while running a Phase 2a/2b program.
Shares rose 6.12%, or $0.87, to $15.08 in midday trading, up from a prior close of $14.21, confirming an upward move. The stock traded between roughly $13.53 and $15.19 during the session. No company-specific announcement was identified ahead of the advance, and the price action is best characterized as an unconfirmed rebound rather than a news-driven re-rating.
No verified news or fundamental catalyst found for the session. With no filing, data readout, partnership, or financing on the tape, the most consistent explanation is technical: shares were recovering part of the 22.74% collapse they suffered on Nov. 16, a drop that occurred even as new bullish coverage landed. That decline left the stock pressing against the $13.50 area, which has now held as support twice in two weeks — intraday lows of $13.53 on Nov. 17 and $13.53 again today, following the $12.39 floor hit in early November.
Liquidity is the second part of the story. Yarrow trades with a float of only a few million shares and a market capitalization near $140 million, so modest order flow can move the quote several percentage points. Turnover on the day was running below the stock's average daily volume of roughly 167,000 shares, meaning the advance was driven by thin supply rather than heavy accumulation. A short-covering bounce after a violent two-day selloff is plausible in that setting; a durable change in fundamentals is not evidenced by the data.
Volume was light relative to the recent norm, a signature of micro-cap drift rather than institutional conviction. Over the past 60 sessions the stock's average absolute daily change was about 5.1%, and six of those sessions produced double-digit moves, including an 18.8% decline on Nov. 4, a 16.6% rally on Nov. 11, and the 22.7% slide on Nov. 16. Today's 6.12% gain is therefore roughly 1.2 times the stock's typical swing — unremarkable against its own history.
The move appeared idiosyncratic rather than sector-driven. There was no broad biotech catalyst or index-level event tied to the timing, and the company's own news flow is quiet. The stock remains far below its 52-week high of $46.95, down roughly 65% from its August level near $40, and about 42% below the $26 per-share price of its roughly $172.5 million September equity offering. That offering overhang helps explain why rallies have struggled to hold. The Nov. 2 close of $17.93 and the Nov. 12 close of $19.63 mark the nearest overhead reference points.
The score runs from 0, meaning no meaningful news and a move entirely normal for the stock, to 100, meaning transformative news and a rare, extreme price move. Yarrow's reading is 13 out of 100.
On the news side, there was no verifiable development on the day; the nearest items — third-quarter results on Nov. 12 and the Jefferies initiation on Nov. 16 — are routine for a company of this size and did not accompany today's buying. On the price side, the 6.12% advance was only about 1.2 times the 5.1% average daily move of the past 60 sessions, and 17 of those sessions produced equal or larger swings. Weak news and an unexceptional move combine into a low score.
Attention turns to the fourth-quarter and full-year 2026 results, expected in early March, when investors will watch the burn rate against the $268.9 million cash balance and any update on enrollment in the DIRECTION-GD Phase 2a cohort. The decisive event remains Phase 2a topline data for YB-101 in Graves' disease, guided for the second half of 2027, alongside multiple-ascending-dose data from partner GenSci's China program.
The analyst consensus stands at Strong Buy across five covering firms, with expectations centered on trial execution rather than near-term revenue — the company has no product sales. Key risks include clinical disappointment, further dilution or resale pressure tied to the September offering, the binary nature of a single-asset pipeline, and the liquidity risk inherent in a thinly traded, sub-$150 million company with a small share count.
Tickeron's Trending AI Robots page is a curated view of automated trading strategies that are performing best under current market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, and this section surfaces only those showing the strongest results right now. The bots differ widely in approach, holding period, risk profile, performance metrics, and the symbols they trade, so a review of the leaderboard can help traders compare methodologies side by side. Explore the page to see which strategies are currently in favor.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
YARW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 2 of 2 cases where YARW's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on YARW as a result. In 2 of 4 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.
Following a +3.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where YARW advanced for three days, in 10 of 13 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YARW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for YARW entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.967) is normal, around the industry mean (3.596). P/E Ratio (0.000) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (2.630) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. YARW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YARW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology